• Satraplatin (INN, codenamed JM216) is a platinum-based antineoplastic agent that was under investigation as a treatment of patients with advanced prostate cancer who have failed previous chemotherapy. (wikipedia.org)
  • Thrombus: Cancer can increase the risk of developing a blood clot, and chemotherapy may increase this risk further. (wikipedia.org)
  • Most types and stages of germ cell cancers of the ovary are treated the same way, with surgery and chemotherapy (chemo). (cancer.org)
  • We show that loss of the DNA repair protein XPA markedly augments the synthetic lethality between MK2 and p53, enhancing anti-tumor responses alone and in combination with cisplatin chemotherapy. (nature.com)
  • Because most tumors are deficient in one or more aspects of the function of the p53 tumor suppressor, either as a consequence of mutations within p53, or impairment of upstream and downstream modulators of p53 activity 19 , targeting MK2 has the potential to selectively enhance tumor cell killing without increasing the genotoxic effects of chemotherapy on normal p53-wild type tissues. (nature.com)
  • In most cases, modern treatment of ovarian cancer includes radical cytoreductive surgery, followed by platinum- and paclitaxel-based systemic chemotherapy ( 5 - 7 ). (spandidos-publications.com)
  • Gemcitabine HCI for Injection is also indicated in combination with Paclitaxel for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. (fresenius-kabi.com)
  • Stordal, Britta , Pavlakis, Nick and Davey, Ross (2009) Treating cisplatin-resistant cancer: a systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy. (dcu.ie)
  • Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer. (dcu.ie)
  • Platinum-based chemotherapy is still an effective treatment for ovarian cancer in spite of severe side effects and development of resistance associated with its use [ 10 ]. (biomedcentral.com)
  • In order to mitigate the side effects and resistance resulting from cisplatin-based chemotherapy, it is essential to investigate new drugs which are non-toxic and work in alternative/similar pathways to cisplatin, thus providing additional therapeutic options in ovarian cancer. (biomedcentral.com)
  • Some of these symptoms can improve after you go through standard ovarian cancer treatments, such as surgery, chemotherapy, and targeted therapy. (myovariancancerteam.com)
  • Ovarian cancer treatments like chemotherapy may also reduce ascites. (myovariancancerteam.com)
  • Paclitaxel (with polyoxyethylated castor oil) injection must be given in a hospital or medical facility under the supervision of a doctor who is experienced in giving chemotherapy medications for cancer. (ankr.us)
  • Their participation in the molecular mechanisms of resistance to cisplatin, a drug commonly used in chemotherapy, is also revised. (hindawi.com)
  • Conclusions In patients with completely staged ovarian clear cell carcinoma, those with stage IA/IC1 disease have an excellent prognosis, regardless of chemotherapy. (bmj.com)
  • Five patients received three to six courses of postoperative adjuvant chemotherapy, with three receiving a bleomycin/etoposide/cisplatin regimen and two receiving a paclitaxel/carboplatin regimen. (bmj.com)
  • it means you have a longer period between platinum-based chemotherapy treatments (carboplatin and cisplatin). (targetovariancancer.org.uk)
  • Chemotherapy and targeted therapies are the most common treatments offered for those with recurrent ovarian cancer. (targetovariancancer.org.uk)
  • This depends on how long it has been since you last had chemotherapy containing a platinum-based chemotherapy (carboplatin or cisplatin). (targetovariancancer.org.uk)
  • If it's been six months or more since your last treatment with carboplatin or cisplatin chemotherapy, the cancer is called platinum-sensitive. (targetovariancancer.org.uk)
  • This is when the cancer comes back between six and 12 months after your last treatment with platinum-based chemotherapy. (targetovariancancer.org.uk)
  • Treatment for ovarian cancer most of the time involves debulking surgery preceded or followed by chemotherapy based on the amount of disease at presentation. (yourhealthmagazine.net)
  • Standard of care for several years now has been the combination of taxol carboplatin chemotherapy. (yourhealthmagazine.net)
  • Treatment of epithelial ovarian cancer is based on the combination of cytoreductive surgery and combination chemotherapy using taxane and platinum. (biomedcentral.com)
  • Over the past three decades, surgical tumor debulking, followed by platinum-based chemotherapy is the standard treatment for advanced ovarian cancer. (biomedcentral.com)
  • Here are some of the treatments that are commonly used for ovarian cancer: Surgery, Chemotherapy, Targeted therapy, Hormone therapy, Radiation therapy. (indianpharmanetwork.co.in)
  • Chemotherapy is a common treatment for ovarian cancer, and several chemotherapy drugs may be used. (indianpharmanetwork.co.in)
  • Paclitaxel: Paclitaxel is a chemotherapy drug that is often used in combination with other drugs to treat ovarian cancer. (indianpharmanetwork.co.in)
  • Carboplatin: Carboplatin is another chemotherapy drug that is commonly used to treat ovarian cancer. (indianpharmanetwork.co.in)
  • Doxorubicin: Doxorubicin is a chemotherapy drug that may be used to treat advanced ovarian cancer. (indianpharmanetwork.co.in)
  • Bevacizumab is often used in combination with chemotherapy to treat advanced ovarian cancer. (indianpharmanetwork.co.in)
  • This drug is often used in patients with advanced ovarian cancer who have already received other treatments, such as chemotherapy. (indianpharmanetwork.co.in)
  • 3 , 4 The current therapy for ovarian cancer is debulking surgery followed by chemotherapy using carboplatin and paclitaxel (PTX). (nature.com)
  • 5 Although ovarian cancer in advanced stages initially appears to be chemotherapy sensitive as response rates to platinum-based therapy exceed 80%, long-term survival remains poor as a result of recurrence and emergence of drug resistance. (nature.com)
  • This is the eighth trial evaluating the use of chemotherapy delivered into the abdomen for ovarian cancer. (ohsu.edu)
  • The Armstrong trial involved 429 women with stage III ovarian cancer who were given chemotherapy following the successful surgical removal of tumors. (ohsu.edu)
  • There has been a prejudice against IP therapy in ovarian cancer because it's an old idea, it requires skill and experience for the surgery and for the chemotherapy, and it's more complicated than IV chemotherapy. (ohsu.edu)
  • But now we have firm data showing that we should use a combination of IP and IV chemotherapy in most women with advanced ovarian cancer who have had successful surgery to remove the bulk of their tumor. (ohsu.edu)
  • Standard treatment for women with stage III ovarian cancer has been surgical removal of the tumor (debulking), followed by six to eight courses of IV chemotherapy given every three weeks with a platinum drug, such as cisplatin or carboplatin, and a taxane drug, such as paclitaxel. (ohsu.edu)
  • The new NCI clinical announcement recommends that women with advanced ovarian cancer who undergo effective surgical debulking receive a combination of IV and IP chemotherapy. (ohsu.edu)
  • IP chemotherapy allows higher doses and more frequent administration of drugs, and it appears to be more effective in killing cancer cells in the peritoneal cavity, where ovarian cancer is likely to spread or recur first. (ohsu.edu)
  • There are now 5 platinum chemotherapy analogues approved for use in the treatment of cancer: cisplatin, carboplatin, oxaliplatin, nedaplatin and lobaplatin. (drjack.world)
  • Chemotherapy uses drugs that target and kill cancer cells. (drjack.world)
  • For years, the standard of care for ovarian cancer has been cytoreductive surgery followed by platinum-based chemotherapy. (drjack.world)
  • Conventional cytotoxic chemotherapy works primarily by interfering with the division and growth of cells, including cancer cells and normal tissue. (valuebasedcancer.com)
  • However, because it is nonselective, cytotoxic chemotherapy can damage healthy cells and can cause severe side effects. (valuebasedcancer.com)
  • 1 Recognizing this challenge, drug developers have been looking for new ways to deliver chemotherapy to address clinical and pharmacologic challenges in the administration of intravenous (IV) cytotoxic drugs, and selectively target cancer cells to improve clinical outcomes and reduce severe adverse events. (valuebasedcancer.com)
  • For example, the industry-sponsored phase III trial comparing first-line crizotinib with chemotherapy (pemetrexed plus either carboplatin or cisplatin) in ALK -rearrangement-positive NSCLC, which constitutes 3% to 5% of NSCLCs, required an international multicenter effort lasting 2.5 years to accrue the required number of research subjects. (onclive.com)
  • Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (yalemedicine.org)
  • I. To compare the incidence of ototoxicity and nephrotoxicity in children, adolescents and young adults with standard risk germ cell tumors treated with carboplatin-based chemotherapy as compared to cisplatin-based chemotherapy. (yalemedicine.org)
  • To compare self-reported peripheral neuropathy and other patient-reported outcomes between children, adolescents and young adults with standard risk germ cell tumors treated with carboplatin-based chemotherapy as compared to cisplatin based chemotherapy. (yalemedicine.org)
  • After Paclitaxel and Carboplatin treatment, followed by a debulking surgery and several lines of chemotherapy due to progression, the patient's disease evolved into carcinomatous meningitis within 6 months after the end of treatment. (spandidos-publications.com)
  • After an initial treatment with neoadjuvant chemotherapy (Paclitaxel, Carboplatin), she underwent optimal debulking surgery. (spandidos-publications.com)
  • Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary. (cancercentrum.se)
  • Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) MVASI®, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease. (mvasi.com)
  • MVASI®, in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in women who received no more than two prior chemotherapy treatments. (mvasi.com)
  • Cisplatin, carboplatin, and paclitaxel are chemotherapy agents approved for the initial treatment of ovarian cancer. (medscape.com)
  • In the event of recurrence, confirmed residual disease, or elevated tumor markers after first-line chemotherapy, recommended treatment consists of paclitaxel (Taxol)-ifosfamide-cisplatin (TIP) or high-dose chemotherapy. (medscape.com)
  • 6 mo from end of treatment), National Comprehensive Cancer Network (NCCN) guidelines strongly recommend referral to a tertiary care center for consultation regarding high-dose chemotherapy, which is potentially curative in some patients. (medscape.com)
  • I. To determine the levels of expression of c-KIT and its ligand, stem cell factor (SCF) in archived, formalin fixed, paraffin embedded primary tumors collected prior to the initiation of first-line chemotherapy. (knowcancer.com)
  • and (7) epithelial ovarian, fallopian tube or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan for platinum-resistant recurrent disease in people receiving no more than two prior chemotherapy regimens. (mmitnetwork.com)
  • Chemotherapy with platinum drugs such as cisplatin, carboplatin, oxaliplatin, or a combination thereof is used to treat a variety of tumors. (eurekaselect.com)
  • [ 1 , 2 ] Currently, both early-stage and advanced-stage fallopian tube cancers are treated in much the same way as ovarian cancers-that is, with surgery followed by chemotherapy. (medscape.com)
  • In fact, most patients with stage I disease are treated with adjuvant chemotherapy because of the luminal structure of the organ and the risk of shedding cells out of the tubes and into the abdominal cavity. (medscape.com)
  • Accordingly, the chemotherapy used to treat primary fallopian tube cancers is based on the standard management of ovarian cancers. (medscape.com)
  • Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) suggest administering three to six cycles of chemotherapy for stage IA-IC disease and six to eight cycles for stage II-IV disease. (medscape.com)
  • As in ovarian cancer, the use of intraperitoneal (IP) chemotherapy must be considered the current standard treatment option in patients with stage II-IV disease. (medscape.com)
  • If the cancer has widely metastasized, chemotherapy is often used alone. (msdmanuals.com)
  • A risk score for the prognosis prediction of the muscle-invasive bladder cancer patients who received gemcitabine plus cisplatin chemotherapy. (cdc.gov)
  • Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy. (cdc.gov)
  • Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept '3G' Trial. (cdc.gov)
  • Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer? (cdc.gov)
  • It is important to use effective contraception while taking this drug and for at least a few months afterwards Many human tumors including testicular, bladder, lung, head, neck, and cervical cancers have been treated with platinum compounds. (wikipedia.org)
  • Women with benign (non-cancerous) germ cell tumors such as mature teratomas (dermoid cysts) are cured by removing the part of the ovary that has the tumor (ovarian cystectomy) or by removing the entire ovary. (cancer.org)
  • As with epithelial ovarian cancers, it is a good idea to consult with a gynecologic oncologist for treating malignant germ cell tumors, especially because these are so uncommon. (cancer.org)
  • About 2-3% of all ovarian cancers are germ cell tumors. (cancer.org)
  • In general, all women with malignant germ cell tumors will have the same staging surgery that is done for epithelial ovarian cancer. (cancer.org)
  • Delivery of siRNA-peptide nanoplexes co-targeting MK2 and XPA to pre-existing p53-deficient tumors in a highly aggressive, immunocompetent mouse model of lung adenocarcinoma improves long-term survival and cisplatin response beyond those of the synthetic lethal p53 mutant/MK2 combination alone. (nature.com)
  • Thus, type I (low-grade serous G1, low-grade endometrioid G1/G2, mucinous or clear cell) tumors are associated with corresponding benign ovarian cystic neoplasms, often developing through an intermediate borderline step and have a better prognosis. (spandidos-publications.com)
  • By live in vivo imaging, ovarian cancer xenograft tumors were reduced after primary treatment with carboplatin. (duke.edu)
  • Advanced ovarian cancer , which also includes advanced fallopian tube or primary peritoneal cancer, includes stage 2 , stage 3 , or stage 4 tumors. (myovariancancerteam.com)
  • When cancer cells spread and tumors get bigger, they can bring about fluid buildup or a blockage in your digestive system or urinary system. (myovariancancerteam.com)
  • Ovarian sex cord stromal tumors were diagnosed or highly suspected from the frozen sections for all patients. (bmj.com)
  • BACKGROUND: Obesity increases breast cancer risk and breast cancer-specific mortality, particularly for people with estrogen receptor (ER)-positive tumors. (bvsalud.org)
  • The results were validated in tumors from obese mice and breast cancer datasets from women with obesity. (bvsalud.org)
  • Comparison of gene expression profiles indicated that tumors from women with obesity shared hallmarks with endocrine-resistant breast cancer cells. (bvsalud.org)
  • Studies have shown that epithelial ovarian cancer is not a single disease but is composed of a diverse group of tumors that can be classified based on distinctive morphologic and molecular genetic features [ 1 ]. (biomedcentral.com)
  • Type I tumors include low-grade serous, low-grade endometrioid, clear cell and mucinous carcinomas and type II include high-grade serous, high-grade endometrioid and undifferentiated carcinomas. (biomedcentral.com)
  • In general, type I tumors are genetically more stable than type II tumors and display a distinctive pattern of mutations that occur in specific cell types. (biomedcentral.com)
  • In terms of origin of ovarian cancer, many of researchers and gynecologic oncologists have traditionally understood that the various different ovarian tumors are all derived from the ovarian surface epithelium (mesothelium) and that subsequent metaplastic changes lead to the development of the different cell types (Table 2 ). (biomedcentral.com)
  • Ovarian cancer is one of the most aggressive female reproductive tract tumors. (nature.com)
  • The drug, which so far has been tested in the lab on ovarian cancer cells and on mice tumors, was unveiled last month in the Proceedings of the National Academy of Sciences (PNAS). (sciencedaily.com)
  • In the trial, the tumors of 647 patients with NSCLC, small cell lung cancer, or thymic malignancies underwent genomic analysis in a search for potentially actionable molecular abnormalities. (onclive.com)
  • This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. (yalemedicine.org)
  • Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. (yalemedicine.org)
  • I. To evaluate whether a strategy of complete surgical resection followed by surveillance can maintain an overall survival rate of at least 95.7% at two years for pediatric, adolescent and adult patients (ages 0- 50 years) with stage I (low risk) malignant germ cell tumors, and at least 98% for patients with ovarian pure immature teratoma. (yalemedicine.org)
  • To compare the event-free survival of a carboplatin versus (vs.) cisplatin-based regimen in the treatment of pediatric, adolescent and young adult patients with standard risk germ cell tumors. (yalemedicine.org)
  • To refine and validate a novel patient-reported measure of hearing outcomes for children, adolescents and young adults with standard risk germ cell tumors. (yalemedicine.org)
  • Pauniaho SL, Salonen J, Helminen M, Vettenranta K, Heikinheimo M, Heikinheimo O. The incidences of malignant gonadal and extragonadal germ cell tumors in males and females: a population-based study covering over 40 years in Finland. (cancercentrum.se)
  • Mayr D, Hirschmann A, Marlow S, Horvath C, Diebold J. Analysis of selected oncogenes (AKT1, FOS, BCL2L2, TGFbeta) on chromosome 14 in granulosa cell tumors (GCTs): a comprehensive study on 30 GCTs combining comparative genomic hybridization (CGH) and fluorescence-in situ-hybridization (FISH). (cancercentrum.se)
  • Mutation of FOXL2 in granulosa-cell tumors of the ovary. (cancercentrum.se)
  • CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. (cancercentrum.se)
  • The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. (cancercentrum.se)
  • Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. (cancercentrum.se)
  • Bjorkholm E, Silfversward C. Granulosa- and theca-cell tumors. (cancercentrum.se)
  • Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. (cancercentrum.se)
  • Ayhan A, Salman MC, Velipasaoglu M, Sakinci M, Yuce K. Prognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases. (cancercentrum.se)
  • Clinical utility of plasma miR-371a-3p in germ cell tumors. (cdc.gov)
  • Epithelial ovarian cancer (EOC) is divided into type I and type II based on histopathological features. (spandidos-publications.com)
  • The most common form is epithelial ovarian cancer (EOC). (spandidos-publications.com)
  • The origin and pathogenesis of epithelial ovarian cancer (EOC) have long been investigated but still poorly understood. (biomedcentral.com)
  • demonstrated in vitro that human epithelial ovarian cancer CD44 + CD117+ cells possessed the properties of let the tumor be chemoresistant to conventional therapies, such as 5FU, docetaxel, cisplatin, and carboplatin [81]. (gsk-3signaling.com)
  • Non-epithelial ovarian cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (cancercentrum.se)
  • The combination used most often is PEB (or BEP), and includes the chemo drugs cisplatin, etoposide, and bleomycin. (cancer.org)
  • Dysgerminomas are usually very sensitive to chemo, and can sometimes be treated with the less toxic combination of carboplatin and etoposide. (cancer.org)
  • Pizzocaro G, Piva L, Salvioni R, Zanoni F, Milani A. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer. (eurekaselect.com)
  • other available platinum analogues-cisplatin, carboplatin, and oxaliplatin-must be given intravenously. (wikipedia.org)
  • Methods: Medline was searched for 1) Cell models of acquired resistance reporting cisplatin, oxaliplatin and paclitaxel sensitivities and 2) Clinical trials of single agent oxaliplatin or paclitaxel salvage therapy for cisplatin/carboplatin-resistant ovarian cancer. (dcu.ie)
  • Results: Oxaliplatin - Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. (dcu.ie)
  • Oxaliplatin as a single agent had a poor response rate in patients with cisplatin-resistant ovarian cancer (8%, n=91). (dcu.ie)
  • Oxaliplatin performed better in combination with other agents for the treatment of platinum-resistant cancer suggesting that the benefit of oxaliplatin may lie in its more favourable toxicity and ability to be combined with other drugs rather than an underlying activity in cisplatin resistance. (dcu.ie)
  • Oxaliplatin therefore should not be considered broadly active in cisplatin-resistant cancer. (dcu.ie)
  • Conclusions: Cellular models reflect the resistance observed in the clinic as the cross resistant agent oxaliplatin has a lower response rate compared to the non-cross resistant agent paclitaxel in cisplatin-resistant ovarian cancer. (dcu.ie)
  • Platin derivatives such as cisplatin, carboplatin or oxaliplatin play important roles in the treatment of malignant diseases such as lung or ovarian cancer. (therawis.com)
  • Oxaliplatin was the last platinum salt administered, since the patient developed a Carboplatin allergy. (spandidos-publications.com)
  • Satraplatin has been developed for the treatment of men with castrate-refractory, metastatic prostate cancer for several reasons. (wikipedia.org)
  • The only Phase III trial with satraplatin (SPARC Trial) was conducted in pretreated metastatic castrate-resistant prostate cancer (CRPC), revealing a 33% reduction in risk of progression or death versus a placebo. (wikipedia.org)
  • Gemcitabine HCI for Injection is indicated in combination with Carboplatin for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy as well as in combination with Cisplatin for the first-line treatment of patients with inoperable, locally advanced (stage IIIA or IIIB), or metastatic (stage IV) non-small cell lung cancer. (fresenius-kabi.com)
  • Metastatic ovarian cancer is when cancer cells have spread from the ovaries to more distant parts of the body. (medicalnewstoday.com)
  • The liver is the most common distant organ for metastatic ovarian cancer to spread to. (medicalnewstoday.com)
  • Surgery is the standard treatment for ovarian cancer, but it may not be suitable for people with metastatic ovarian cancer, especially if the cancer has spread throughout the abdominal cavity. (medicalnewstoday.com)
  • Among these miRNAs, we focused on miRNA-31 (miR-31) because miR-31 was the only miR that has been reported to regulate tumor phenotype, an anti-metastatic effect in breast cancer. (nature.com)
  • Eligible patients have not been treated previously and have measurable or evaluable metastatic colorectal cancer, an Eastern Cooperative Oncology Group performance status of 2 or less, and adequate bone marrow, liver, and renal functions. (cancernetwork.com)
  • The results of this study could lead to a change to oral therapy as the standard of care for metastatic colorectal cancer, providing the efficacy and toxicity of UFT/leucovorin are at least equivalent due to the ease of administration and patient preference for oral regimens. (cancernetwork.com)
  • Patients with previously untreated metastatic colorectal cancer with evaluable or measurable disease and good performance status (Eastern Cooperative Oncology Group £ 2) are eligible for entry into this study. (cancernetwork.com)
  • Participant must have histologically confirmed, locally advanced (i.e., not amenable to curative surgery and/or radiation therapy) or metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen. (uclahealth.org)
  • Participant must have histologically documented, platinum resistant, advanced (metastatic and/or unresectable) high-grade serous/endometrioid ovarian, primary peritoneal, or fallopian tube cancer. (uclahealth.org)
  • Metastatic Renal Cell Carcinoma (mRCC) MVASI®, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC). (mvasi.com)
  • MVASI®, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix. (mvasi.com)
  • Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer. (cdc.gov)
  • Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. (cdc.gov)
  • Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. (cdc.gov)
  • It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube. (biomedcentral.com)
  • Ovarian Cancer (OC) MVASI®, in combination with carboplatin and paclitaxel, followed by Avastin alone, is used for the treatment of patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery. (mvasi.com)
  • MVASI®, either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by Avastin alone, is approved for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (mvasi.com)
  • Studies suggest that many primary peritoneal cancers and some ovarian cancers (such as high-grade serous carcinomas) actually start in the fallopian tubes. (cancer.org)
  • Its relative ease of administration, potential lack of cross-resistance with other platinum agents, clinical benefits seen in early studies of prostate cancer, and an unmet need in this patient population after Docetaxel failure at that time. (wikipedia.org)
  • Another alternative is to combine carboplatin with docetaxel. (medscape.com)
  • Docetaxel injection may cause low levels of white blood cells in the blood. (medlineplus.gov)
  • Docetaxel injection is used alone or in combination with other medications to treat certain types of breast, lung, prostate, stomach, and head and neck cancers. (medlineplus.gov)
  • Docetaxel injection is also sometimes used to treat ovarian cancer (cancer that begins in the female reproductive organs where eggs are formed). (medlineplus.gov)
  • Based on this updated knowledge, when discussing contraception to avoid future pregnancy, some doctors recommend removal of the fallopian tubes, rather than tying or banding the tubes, in order to lower the risk of ovarian/fallopian tube cancers. (cancer.net)
  • Epithelial carcinoma makes up 85% to 90% of ovarian/fallopian tube cancers. (cancer.net)
  • Studies have shown that fallopian tube cancers develop in women with BRCA gene mutations more often than doctors had previously suspected. (cancer.org)
  • Cells from these very early fallopian tube cancers can become detached and then stick to the surface of the peritoneum or the ovaries. (cancer.org)
  • Surgery is the initial therapy for stage I-IV fallopian tube cancers. (medscape.com)
  • Only a small percentage of women with epithelial fallopian tube cancers are treated with surgery alone. (medscape.com)
  • no randomized trials have specifically addressed fallopian tube cancers. (medscape.com)
  • An acquired resistance to cisplatin/carboplatin in ovarian cancer was discovered due to insufficient amounts of platinum reaching the target DNA or failure to achieve cell death. (wikipedia.org)
  • In a phase I study from Vanderbilt University, seven of eight patients with squamous cell carcinoma of the head and neck, who were treated with 10 to 30 mg of satraplatin thrice a week concurrently with radiotherapy achieved a complete response. (wikipedia.org)
  • Objective We sought to describe clinicopathologic and treatment factors associated with oncologic outcomes in patients with early-stage ovarian clear cell carcinoma undergoing complete staging and in a sub-set of these patients undergoing fertility-conserving surgery. (bmj.com)
  • Methods We retrospectively identified patients with ovarian clear cell carcinoma initially treated at our institution from January 1, 1996 to March 31, 2020. (bmj.com)
  • Mismatch repair deficiency is common but not associated with prognosis in early-stage ovarian clear cell carcinoma. (bmj.com)
  • Fertility conservation may be safe in appropriately selected women with early-stage ovarian clear cell carcinoma. (bmj.com)
  • In early-stage ovarian clear cell carcinoma, data are difficult to interpret as most research includes patients without comprehensive staging. (bmj.com)
  • The larger expectation for improved prognosis in ovarian carcinoma is related to the use of the new biological agents. (biomedcentral.com)
  • 12. 50-year-old man with T2N2M0O EBV + Nasopharynx carcinoma is treated with 70 Gy radiation with concurrent cisplatin and has complete resolution of disease. (examyear.com)
  • This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignature® test status. (uclahealth.org)
  • Biochemical recurrence (eg, CA-125 in ovarian carcinoma) only is not considered as disease progression. (uclahealth.org)
  • 13009 Marseille, France Human papillomaviruses (HPV) have been implicated in the pathogenesis of human squamous cell carcinoma, especially of cervical carcinomas. (coek.info)
  • HPV DNA is found in two of 18 cases of squamous cell carcinoma (II %), in one of 4 cases of adenocarcinoma, and in two of 7 cases of neuro-endocrin cancers. (coek.info)
  • However, investigators have demonstrated precursor cancerous lesions in the fallopian tube (tubal in-situ carcinoma [TIC]) and have provided evolutionary evidence that many advanced serous ovarian cancers originate in the fallopian tubes. (medscape.com)
  • Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma. (cdc.gov)
  • The drug has also been used in the treatment of lung and ovarian cancers. (wikipedia.org)
  • In addition some cisplatin resistant tumour cell lines were sensitive to satraplatin treatment in vitro. (wikipedia.org)
  • Other drug combinations may be used to treat cancer that has recurred (come back) or hasn't responded to treatment. (cancer.org)
  • These findings establish a mechanism for co-targeting DNA damage-induced cell cycle checkpoints in combination with repair of cisplatin-DNA lesions in vivo using RNAi nanocarriers, and motivate further exploration of ASL as a generalized strategy to improve cancer treatment. (nature.com)
  • The concept of synthetic lethality (SL) holds great promise for the treatment of human cancers, best exemplified by the now widespread use of PARP inhibitors in BRCA mutant cancers. (nature.com)
  • Numerous epidemiological and preclinical studies support a role of vitamin D compounds in cancer prevention and treatment in colorectal, breast, prostate, ovarian, bladder, lung and skin cancers and leukemia ( 1 , 5 , 6 ). (jcancer.org)
  • The histopathology of ovarian cancer is heterogeneous, and each subtype harbors specific genetic mutations that can be used for diagnostics and targeted treatment. (spandidos-publications.com)
  • Continued treatment with carboplatin was accompanied by an increase in tumor signal, whereas there was little or no increase in tumor signal observed with subsequent treatment with UCN-01 or oltipraz. (duke.edu)
  • A blood test for elevated levels of the protein CA125 is used to inform doctors if ovarian cancer is present and how it is responding to treatment. (animalresearch.info)
  • These treatments are commonly already used in breast cancer treatment. (animalresearch.info)
  • This article looks at how ovarian cancer can spread to other parts of the body, as well as the treatment options and outlook. (medicalnewstoday.com)
  • In contrast, in cisplatin-resistant cells, BT-cisplatin combination treatment displayed synergistic effects at most of the drug ratios/concentrations. (biomedcentral.com)
  • Low doses of BT and cisplatin enhanced efficiency of cisplatin treatment in all the ovarian cancer cell lines tested. (biomedcentral.com)
  • The poor survival rate for women with platinum-resistant ovarian carcinomas demands alternative treatment strategies. (biomedcentral.com)
  • Managing cancer symptoms and treatment side effects can help your treatments work more effectively and give you a better quality of life. (myovariancancerteam.com)
  • Alternatively, you may have early stage cancer that disappears following treatment, but could become more advanced if it comes back. (myovariancancerteam.com)
  • Your doctor will order laboratory tests before and during your treatment to check the number of white blood cells in your blood. (ankr.us)
  • Your doctor will delay or interrupt your treatment if the number of white blood cells is too low. (ankr.us)
  • Paclitaxel (brand name-Taxol) is an FDA-approved treatment for breast cancer, ovarian cancer, pancreatic cancer, and non-small cell lung cancer (NSCLC). (ankr.us)
  • The treatment is given every 1 to 3 weeks, depending on the type of cancer and your treatment regimen. (ankr.us)
  • Objective To analyze the clinical characteristics, diagnosis, and treatment of ovarian juvenile granulosa cell tumor. (bmj.com)
  • Conclusions Fertility-sparing surgery is the treatment of choice for ovarian juvenile granulosa cell tumor and the overall prognosis is good. (bmj.com)
  • RESULTS: FGF1 stimulated ER phosphorylation independently of estradiol in cells that grow in obese female mice after estrogen deprivation treatment. (bvsalud.org)
  • The first-line treatment for many patients with ER-positive breast cancer is inhibition of estrogen synthesis using aromatase inhibitors. (bvsalud.org)
  • We help answer your questions about ovarian cancer recurrence and look at treatment options. (targetovariancancer.org.uk)
  • Treatment will usually be recommended when your team has found clear evidence of the cancer growing on scans. (targetovariancancer.org.uk)
  • it may improve your quality of life, because if the cancer comes back again over the course of time, you'll spend less time having treatment and dealing with the side effects. (targetovariancancer.org.uk)
  • It's also okay to start treatment as soon as it's been confirmed that the cancer has come back. (targetovariancancer.org.uk)
  • Which treatment you receive will depend on what type of ovarian cancer you have, how well you responded to your original treatment and your personal wishes. (targetovariancancer.org.uk)
  • Mutation testing by Caris molecular intelligence demonstrated a breast cancer 2 gene mutation and further treatment with carboplatin and veliparib achieved disease stabilisation. (biomedcentral.com)
  • 80% and 40-60%, respectively, after first-line treatment with carboplatin and paclitaxel, most patients will eventually relapse with a median progression-free survival of 18 months [ 2 ]. (biomedcentral.com)
  • IPN, New Delhi can facilitate Ovarian cancer patient to "import of Medicines For Ovarian Cancer Treatment" for personal use under "patient name basis" treatment in India. (indianpharmanetwork.co.in)
  • The treatment of ovarian cancer depends on various factors such as the stage of the cancer, the age and health of the patient, and the extent to which the cancer has spread. (indianpharmanetwork.co.in)
  • Targeted therapy is a type of cancer treatment that works by targeting specific molecules or pathways that are involved in the growth and spread of cancer cells. (indianpharmanetwork.co.in)
  • These drugs are often used in patients with advanced ovarian cancer and a BRCA gene mutation, as they are more likely to respond to this type of treatment. (indianpharmanetwork.co.in)
  • Immunotherapy is a type of cancer treatment that works by stimulating the patient's immune system to recognize and attack cancer cells. (indianpharmanetwork.co.in)
  • Paclitaxel (PTX) is widely used for the treatment of ovarian cancer. (nature.com)
  • Furthermore, co-treatment of KFr13Tx cells with MET inhibitors sensitized the tumor cells to PTX both in vitro and in vivo . (nature.com)
  • The National Cancer Institute (NCI), part of the National Institutes of Health, today issued an announcement encouraging treatment with anticancer drugs via two methods, after surgery, for women with advanced ovarian cancer. (ohsu.edu)
  • IP therapy is not a new treatment approach, but it has not been widely accepted as the gold standard for women with ovarian cancer," said Armstrong. (ohsu.edu)
  • The global endometrial cancer market has been segmented on the basis of diagnosis, end users, treatment, and lastly region. (medgadget.com)
  • Leaders from UT Health San Antonio and MD Anderson Cancer Center have discussed the partnership between the institutions for cancer research and treatment and its benefit to local cancer patients. (medgadget.com)
  • Scientists have discovered a new type of drug for the treatment of ovarian cancer that works in a way that should not only decrease the number of doses that patients need to take, but also may make it effective for patients whose cancer has become drug resistant. (sciencedaily.com)
  • https://targetovariancancer.org.uk/about-ovarian-cancer/your-situation/my-ovarian-cancer-has-come-back/treatment › your-situation › tre. (drjack.world)
  • One proposal to begin to explore the benefits of targeted antineoplastics in the setting of specific molecular abnormalities has been to develop a socalled "basket trial" where patients with different types of cancers with varying treatment histories may be permitted entry, assuming a well-defined molecular target is present within their cancer. (onclive.com)
  • PARP inhibitors are considered as a treatment revolution in ovarian cancer management. (spandidos-publications.com)
  • Due to the presence of a pathogenic mutation and a loss of wild‑type BRCA2 allele, a maintenance treatment by Olaparib was initiated after radiotherapy and Cisplatin monotherapy. (spandidos-publications.com)
  • MVASI® is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body. (mvasi.com)
  • In the treatment recommendations below, note that carboplatin is dosed to achieve a targeted area under the curve (AUC), which is defined as the area under the concentration-versus-time curve and expressed in mg/mL/min. (medscape.com)
  • The incidence of cervical cancer has decreased steadily over the past several decades because of HPV vaccination, cervical cancer screening, and treatment of CIN. (msdmanuals.com)
  • About 85-90% of ovarian cancers are a type of cancer known as epithelial ovarian carcinomas, which can be high or low grade. (medicalnewstoday.com)
  • p53-aberrant clear cell carcinomas are rare, but this may be associated with poor prognosis, even in early-stage disease. (bmj.com)
  • Squamous cell (epidermoid) carcinomas are a type of NSCLC usually found inside of the airways in the lungs. (mvasi.com)
  • Large cell (undifferentiated) carcinomas can be found anywhere in the lungs. (mvasi.com)
  • In two previous studies concerning squamous cell carcinomas of the lung, DNA to HPV subtypes 6/11/16/18 (and 31133135 for one study) was detected by in situ hybridization in 7 to 30% ofthe cases. (coek.info)
  • No case of the two large cell undifferentiated carcinomas was positive. (coek.info)
  • No morphologic changes consistent with HPV lesions were seen, and squamous metaplasia was observed only in squamous cell carcinomas. (coek.info)
  • The frequency of II % among the squamous cell carcinomas is near those found by previous studies, whereas PCR is theoretically more sensitive than in situ hybridization. (coek.info)
  • Satraplatin appears to have clinical activity against a variety of malignancies such as Breast Cancer, Prostate cancer and Lung cancer. (wikipedia.org)
  • Further well designed clinical trials should be conducted to better understand the role of calcitriol in cancer therapy. (jcancer.org)
  • In line with clinical experience, EOC type I samples were generally more resistant than type II samples to both standard cytotoxic drugs and the TKIs, reaching statistical significance for cisplatin (P=0.03) and dasatinib (P=0.002). (spandidos-publications.com)
  • To identify clinically relevant platin-specific biomarkers we used the Kaplan-Meier plotter for ovarian and lung cancer ( www.kmplot.com ) to analyze the impact of individual genes on the clinical outcome of ovarian and lung cancer patients. (therawis.com)
  • Methods The clinical and pathological data of six patients with ovarian juvenile granulosa cell tumor was collected. (bmj.com)
  • Follicular dendritic cell sarcoma is a rare tumour with clinical behaviour covering a spectrum from indolent to aggressive disease. (biomedcentral.com)
  • Follicular dendritic cell sarcoma (FDCS) is an uncommon neoplasm of mesenchymal stem cell origin whose clinical course displays much variability. (biomedcentral.com)
  • The clinical announcement to surgeons and other medical professionals who treat women with ovarian cancer was made with the support of six professional societies and advocacy groups. (ohsu.edu)
  • The announcement coincides with results, published in the New England Journal of Medicine,* of results from a large clinical trial by Deborah Armstrong, M.D., medical oncologist and an associate professor at Johns Hopkins Kimmel Cancer Center in Baltimore and her colleagues in an NCI-supported research network known as the Gynecologic Oncology Group (GOG). (ohsu.edu)
  • The National Cancer Institute wants to make certain that the results of clinical research are rapidly disseminated to both health care providers and patients, in order to ensure that life-enhancing cancer treatments are widely available," said NCI Director Andrew C. von Eschenbach, M.D. (ohsu.edu)
  • Maurie Markman, MD, discusses how the molecular complexities of cancer necessitate that clinical research evolves beyond the basket trial design. (onclive.com)
  • But what if an investigator, research team, or biotech company desired to examine the clinical utility of an antineoplastic in a patient population representing an even smaller proportion of patients with NSCLC such as in the 1% of the patient population with ROS1 abnormalities, 2 or in a larger percentage of patients representing 4%-6% of patients with a less common tumor type such as ovarian cancer? (onclive.com)
  • I. To prospectively determine the correlation of tumor marker decline (alpha-FP and beta-HCG) with clinical outcome in low and standard risk germ cell tumor patients. (yalemedicine.org)
  • However, in view of the excellent chemosensitivity of germ cell cancers, clinical judgment can be used if surgical management would significantly increase postoperative morbidity. (medscape.com)
  • Platinum drugs are a class of chemotherapeutic drugs that affect the cell cycle, and the main site of action is the DNA of cells, which are common chemotherapeutic drugs in clinical practice. (eurekaselect.com)
  • Efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian Cancer: A GINECO/GCIG randomized clinical trial. (eurekaselect.com)
  • Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. (cdc.gov)
  • Five leads were tested in additional cancer cell lines of which, doxorubicin, mitoxantrone, and mithramycin demonstrated synergy in all lines. (biomedcentral.com)
  • investigating about Müllerian Inhibiting Substance with the aim of inhibit stem/progenitors in EOC, identified eight marker panel on three human ovarian cancer cell lines and found that the combination of Epcam+, CD24+, and CD44+ formed more colonies than other marker combinations. (gsk-3signaling.com)
  • Drug resistance to currently used chemotherapies is the fundamental cause of recurrence and poor overall survival in ovarian cancer patients [ 1 - 3 ]. (biomedcentral.com)
  • discovered that the presence of ALDH(+)CD133(+) cells in debulked primary tumor specimens correlated with reduced disease-free and overall survival in ovarian cancer patients [31]. (gsk-3signaling.com)
  • Gemcitabine kills cells that are dividing. (valuebasedcancer.com)
  • After the gemcitabine nucleotide is incorporated into DNA, only one more nucleotide is added to the growing DNA strands, which eventually leads to apoptotic cell death. (valuebasedcancer.com)
  • Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China. (cdc.gov)
  • Isolated EOC tumor cells obtained at surgery were investigated for their sensitivity to seven standard cytotoxic drugs and nine TKIs using a short‑term fluorescent microculture cytotoxicity assay (FMCA). (spandidos-publications.com)
  • The clinically observed relative drug resistance of EOC type I, as well as in patients previously treated, is at least partly due to mechanisms in the tumor cells. (spandidos-publications.com)
  • Although TRAIL and agonistic antibodies to death receptors 4 and 5 are promising candidates for cancer therapy, many tumor cells are inherently resistant or acquire resistance to TRAIL-mediated apoptosis. (biomedcentral.com)
  • Additionally, the allelic frequency observed indicated that the mutation was present at the homozygous status in tumor cells. (spandidos-publications.com)
  • to select and enrich population of CD133(+) ovarian tumor cells that are characterized by a higher clonogenic efficiency and proliferative potential [77]. (gsk-3signaling.com)
  • Advanced or recurrent ovarian cancer may cause several symptoms that lead to pain or discomfort. (myovariancancerteam.com)
  • This isn't an option when the cancer is in both ovaries. (cancer.org)
  • If cancer has spread beyond the ovaries , debulking surgery may be done as a part of the initial surgery. (cancer.org)
  • Ovarian cancer refers to cancer that starts in the ovaries. (medicalnewstoday.com)
  • If you have stage 4 ovarian cancer, this means the cancer has spread to parts of your body far away from your ovaries. (myovariancancerteam.com)
  • Because the surfaces of the ovaries, the lining of the fallopian tubes, and the covering cells of the peritoneum are made up of the same types of cells, most of these diseases look alike under a microscope. (cancer.net)
  • Rarely, peritoneal cancer can develop after ovaries and fallopian tubes have been removed. (cancer.net)
  • Ovarian cancer is a type of cancer that starts in the ovaries, which are the female reproductive organs that produce eggs. (indianpharmanetwork.co.in)
  • For example, mathematical models have been developed that help estimate how many years of life an average woman with a BRCA mutation might gain by having both ovaries and fallopian tubes removed to prevent a cancer from developing. (cancer.org)
  • This theory has important implications for preventing ovarian cancer because having the ovaries removed early can cause problems from lack of estrogen, such as bone loss, cardiovascular disease, and menopause symptoms. (cancer.org)
  • This approach lets women keep their ovaries functioning for longer, but because of that, it might not help breast cancer risk as much. (cancer.org)
  • Staging fallopian tube cancer involves the removal of both fallopian tubes and of the ovaries, uterus, cervix, infracolic omentum, and retroperitoneal lymph nodes, in addition to peritoneal washings and peritoneal biopsies. (medscape.com)
  • Low levels of plasma 25(OH)D 3 are associated with higher cancer incidence and mortality in men in colorectal, breast, lung and prostate cancers ( 7 - 10 ). (jcancer.org)
  • Ovulatory surges of human CG prevent hormone-induced granulosa cell tumor formation leading to the identification of tumor-associated changes in the transcriptome. (cancercentrum.se)
  • Pectasides D, Pectasides E, Psyrri A. Granulosa cell tumor of the ovary. (cancercentrum.se)
  • Ovarian granulosa cell tumor and increased risk of breast cancer. (cancercentrum.se)
  • When the term "ovarian cancer" is used, it includes both fallopian tube and peritoneal cancers because it may be unclear where the cancer started. (cancer.net)
  • Just as with ovarian cancer, some peritoneal cancers may begin in the fallopian tubes and spread from the end of the fallopian tube into the peritoneal cavity. (cancer.net)
  • One of the most investigated and promising molecular targeted drugs in ovarian cancer is bevacizumab, a monoclonal antibody directed against VEGF. (biomedcentral.com)
  • A few recent studies demonstrated positive results of bevacizumab on progression-free survival in ovarian cancer patients, however, investigation of molecular targeting drugs in patients with ovarian cancer are still underway. (biomedcentral.com)
  • Especially in combination with radiotherapy it appears to have good efficacy in combination for lung and squamous head and neck cancer. (wikipedia.org)
  • Most women with germ cell cancer will need to be treated with combination chemo for at least 3 cycles. (cancer.org)
  • Combination drug therapy appears a promising approach to overcome drug resistance and reduce drug-related toxicities in ovarian cancer treatments. (biomedcentral.com)
  • The primary objectives of this study are to determine the nature of the interactions between BT and cisplatin and to understand the mechanism(s) of action of BT-cisplatin combination. (biomedcentral.com)
  • The efficacy of the BT-cisplatin combination depends upon the cell type and concentrations of cisplatin and BT. (biomedcentral.com)
  • Combining low doses of cisplatin with subtherapeutic doses of BT can ultimately lead to the development of an innovative combination therapy to reduce/prevent the side effects normally occurring when high doses of cisplatin are administered. (biomedcentral.com)
  • It is used by itself or in combination with other chemotherapies (like cisplatin or carboplatin) and immunotherapies (like pembrolizumab). (ankr.us)
  • The identification of a number of FDA-approved drugs as TRAIL sensitizers can expand chemotherapeutic options for combination treatments in prostate and pancreatic cancer diseases. (biomedcentral.com)
  • It is often used in combination with paclitaxel and works by damaging the DNA in cancer cells, preventing them from growing and dividing. (indianpharmanetwork.co.in)
  • This study demonstrated miR31-dependent regulation of MET for chemoresistance of ovarian cancer, raising the possibility that combination therapy with a MET inhibitor and PTX will increase PTX efficacy. (nature.com)
  • We are exploring combination studies in order to find synergy between our drug and first-line therapy for ovarian cancer," Neamati said. (sciencedaily.com)
  • However, because of a more tolerable toxicity profile, the combination of carboplatin and paclitaxel is preferred. (medscape.com)
  • It is indicated for advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy and is used in combination with carboplatin. (medscape.com)
  • As the test has a high false positive rate, it is generally not recommended for women with an average risk of ovarian cancer. (animalresearch.info)
  • These tests can identify genetic features that may increase the risk of ovarian cancer. (medicalnewstoday.com)
  • Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial. (cdc.gov)
  • Although clear cell type is categorized in indolent type, it is known to show relatively strong resistance to carboplatin and paclitaxel regimen and thus poor prognosis compared to serous adenocarcinoma, especially in advanced stages. (biomedcentral.com)
  • To compare the EFS of a carboplatin-based regimen (BEC) vs. a cisplatin-based regimen (BEP) in adolescents and young adults (ages 11 - 25 years) with standard risk GCT. (yalemedicine.org)
  • Because the addition of other drugs to this regimen has proved disappointing, Katsumata et al studied the use of a dose-dense regimen, in which paclitaxel is given on days 1, 8, and 15 and carboplatin is given on day 1. (medscape.com)
  • In the current work, we screened a small library of fifty-five FDA and foreign-approved anti-neoplastic drugs in order to identify candidates that sensitized resistant prostate and pancreatic cancer cells to TRAIL-induced apoptosis. (biomedcentral.com)
  • Drugs demonstrating the highest synergy were selected as leads and tested in different prostate and pancreatic cancer cell lines, and one immortalized human pancreatic epithelial cell line. (biomedcentral.com)
  • Fourteen drugs were identified as having synergy with TRAIL, including those whose TRAIL sensitization activities were previously unknown in either prostate or pancreatic cancer cells or both. (biomedcentral.com)
  • At these low concentrations, mitoxantrone demonstrated selectivity toward malignant cells over normal pancreatic epithelial cells. (biomedcentral.com)
  • The recommended doses of Infugem in patients with breast cancer, ovarian cancer, NSCLC, or pancreatic cancer are listed in Table 1 . (valuebasedcancer.com)
  • Role of genetic testing in hepatic, pancreatic, and biliary cancers. (cdc.gov)
  • Because BRCA mutations are observed in fewer than 10% of cancer patients (cBioPortal: 6.7%) 11 , 12 , 13 the identification of additional genes that share synthetic lethal sensitivity relationships with mutated oncogenes or tumor suppressors would greatly enhance the implementation of tumor cell-specific synthetic lethal sensitivity to improve an anticancer therapeutic response. (nature.com)
  • Our results suggest that novel combinations such as BT and cisplatin might be an attractive therapeutic approach to enhance ovarian cancer chemosensitivity. (biomedcentral.com)
  • thus, it may be a successful therapeutic target in ovarian cancer. (medscape.com)
  • for example, non-small cell lung cancer (NSCLC) versus EGFR -mutation-positive NSCLC. (onclive.com)
  • We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. (cancer.org)
  • The graph highlights one of these genes in the platin resistance signature identifying non-small lung cancer patients with good (black line) vs poor survival (red line). (therawis.com)
  • Because PACMA31's strategy is different than that of current anticancer drugs, it has the potential to help patients who do not respond to paclitaxel or cisplatin. (sciencedaily.com)
  • If patients are treated with cisplatin, paclitaxel should be administered as a 24-hour infusion to decrease the risk of neurotoxicity. (medscape.com)
  • The oral mucositis (OM) represents a frequent inflammatory condition in cancer patients, and poor oral hygiene has been related as a predisposing factor for its onset. (bvsalud.org)
  • Although TRAIL and agonistic antibodies to DR4 and DR5 are considered safe and promising candidates in cancer therapy, many malignant cells are resistant to DR-mediated, TRAIL-induced apoptosis. (biomedcentral.com)
  • TRAIL has attracted significant attention in recent years due to its ability to selectively induce apoptosis in transformed (malignant) cells while demonstrating little cytotoxicity in normal cells [ 2 - 7 ]. (biomedcentral.com)
  • Ova 1 with radiologic studies detected 92% of malignant ovarian masses compared to 72% without ova 1. (yourhealthmagazine.net)
  • Determining if an ovarian mass is malignant prior to surgery is extremely important because the surgery for ovarian cancer is much more extensive than surgery for a benign mass and needs to be done by a gynecologic oncologist. (yourhealthmagazine.net)
  • Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. (cancercentrum.se)
  • We describe a case of progressive follicular dendritic cell sarcoma of the lung and pleura, treated based on knowledge of the tumour's molecular aberrations. (biomedcentral.com)
  • What is Non-Squamous Non-Small Cell Lung Cancer? (mvasi.com)
  • The types of non-small cell lung cancer are named for the kinds of cells in which they occur and how the cells look under a microscope. (mvasi.com)
  • Adenocarcinomas make up about 40% of lung cancers. (mvasi.com)
  • They usually occur in smokers and they are also the most common lung cancer seen in nonsmokers. (mvasi.com)
  • Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives. (cdc.gov)
  • A narrative review of genetic biomarkers in non-small cell lung cancer: an update and future perspectives. (cdc.gov)
  • Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction. (cdc.gov)
  • Satraplatin is similar in toxicity profile to carboplatin, with no nephrotoxicity, neurotoxicity, or ototoxicity observed. (wikipedia.org)
  • New information about how much BRCA1 and BRCA2 gene mutations increase ovarian cancer risk is helping women make practical decisions about prevention. (cancer.org)
  • Scholars@Duke publication: Targeting Dormant Ovarian Cancer Cells In Vitro and in an In Vivo Mouse Model of Platinum Resistance. (duke.edu)
  • We found that miR-31 was downregulated in KFr13Tx cells, and that re-introduction of miR31 re-sensitized them to PTX both in vitro and in vivo . (nature.com)
  • Body mass index (BMI) is used to define obesity, but it may not be the best predictor of breast cancer risk or prognosis on an individual level. (bvsalud.org)
  • In addition, lower levels of miR31 and higher expression of MET in human ovarian cancer specimens were significantly correlated with PTX chemoresistance and poor prognosis. (nature.com)
  • Cerebral progression of ovary cancer is a rare event with a dark prognosis, death happening within a few weeks. (spandidos-publications.com)
  • This chapter traces the ancient history of PDT and its stages of development to date for diagnosing and treating various types of cancers, and it ends with a synopsis of the recent trends in PDT applications. (rsc.org)
  • EOC can include cells of origin from both the ovarian surface epithelium and the fallopian tube ( 2 ). (spandidos-publications.com)
  • UCN-01, a kinase inhibitor/mitochondrial uncoupler that has been shown to lead to Puma-induced mitochondrial apoptosis as well as ATP synthase inhibitor oligomycin, demonstrated effectiveness against spheroids, whereas spheroids were refractory to cisplatin and paclitaxel. (duke.edu)
  • For women with a family history of breast or ovarian cancer, doctors can offer tests for forms of genes that are linked to these cancers. (animalresearch.info)
  • The key factors driving this market are changes in sedentary lifestyle, growing consumption of unhealthy diet, growing obesity among women, increase in menopausal hormone therapy, increasing occurrence of Polycystic Ovarian Syndrome (PCOS), increasing prevalence of breast or ovarian tumor, rising prevalence of endometrial cancer, and various socioeconomic factors. (medgadget.com)